ANXA2 and breast cancer: To determine whether serum exo-AnxA2 could be a potential diagnostic tool for aggressive breast cancer, receiver operating characteristic (ROC) curves were used to compare the serum exo-AnxA2 levels from 169 breast cancer patients and 68 non-cancer patients.